Results 71 to 80 of about 1,071 (121)

Optimizing FAPI homodimers for theranostic applications: The impact of the linker design in DOTAGA.Glu₂.(FAPI)₂ and DOTAGA.PEG₂.Glu.(FAPI)₂. [PDF]

Eur J Nucl Med Mol Imaging
Kumar N, Bilinska A, Menéndez E, Stephan S, Rösch F, Rominger A, Gourni E.   +6 more
europepmc   +1 more source

Coumarin Conjugation as an Albumin-Binding Strategy to Modulate the Pharmacokinetics of FAPI Radiotracers. [PDF]

ACS Omega
Xiong J, Pei Y, Guo X, Yang Y, Wu L, Fan L, Hou H, Yang Z, Li J.   +8 more
europepmc   +1 more source

Diagnostic utility of FAPI PET/CT in radioiodine-refractory thyroid cancer and TENIS syndrome: a systematic review. [PDF]

Oncol Rev
Al-Ibraheem A, Ruzzeh S, Al-Muhtaseb A, Abdlkadir AS, Moghrabi S, Shi H, Dadgar H, Al-Foqahaa M, Abdulrahman M, Al-Qasem S, Mohamad I, Sykiotis GP.   +11 more
europepmc   +1 more source

Assessment of active fibrotic remodeling in patients with idiopathic pulmonary fibrosis (IPF)/progressive pulmonary fibrosis (PPF) using dual-time-point [68Ga]Ga-FAPI-46-PET/CT

European Journal of Radiology
Michael Grunert, Virginia Horn, Josefine Christine Baudrexl, Patrick Buechele, Carsten Hackenbroch, Burkhard Klemenz, Ambros J. Beer, Konrad Steinestel, Daniel Gagiannis   +8 more
openaire   +1 more source

⁶⁸Ga-FAPI-PET/CT in extra-cervical CUP: Head-to-Head Comparison of ⁶⁸Ga-FAPI-46 with ¹⁸F-FDG in 13 patients. [PDF]

Eur J Nucl Med Mol Imaging
Spektor AM, Zapata Bonilla SA, Mildenberger P, Kilburg A, Driess D, Winter E, Kloth M, Schreckenberger M, Bäuerle T, Kindler T, Haberkorn U, Pouyiourou M, Krämer A, Bochtler T, Röhrich M.   +14 more
europepmc   +1 more source

Application of theranostics in thyroid cancer management.

J Clin Endocrinol Metab
Sridhar A, Behiri N, Klubo-Gwiezdzinska J.   +2 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

[68Ga]Ga-FAPI-46 PET/MRI for Therapy Monitoring of Desmoid Tumors

Clinical Nuclear Medicine
Desmoid tumors (DT) are locally aggressive and show a high potential for recurrence. Magnetic resonance imaging (MRI) is the preferred modality for DT staging due to its high soft-tissue contrast. However, MRI was found to have limitations for therapy monitoring.
Anna Hinterberger, Jens Jakob, Franka Menge, Güllü Davarci, Freba Grawe   +4 more
openaire   +2 more sources